TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10529526

Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution applied twice a year on the enamel surfaces of the first permanent molars for 5 years
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo solution applied twice a year on the enamel surfaces of the first molars for 5 years
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution in low-SMS subjects
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo solution in low-SMS subjects
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution in high-SMS subjects
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo solution in high-SMS subjects
Number of subjects: 284
Study: 8685949

Group type: COMPARATOR
Intervention: CMV immune globulin prophylaxis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CMV viremia
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Invasive fungal disease
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Abdominal reoperation
Number of subjects: 141
Study: 1522289

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel (daily application for one week)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study: 6443719

Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative external drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative internal drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical well-accepted drainage period of 2-4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous approach
Number of subjects: 0
Study: 31371150

Group type: EXPERIMENTAL
Intervention: Lower frequency (28 kHz) phacoemulsification
Number of subjects: 160

Group type: COMPARATOR
Intervention: Higher frequency (42 kHz) phacoemulsification
Number of subjects: 160
Study: 29710060

Group type: EXPERIMENTAL
Intervention: Self-management program plus standard care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 25881564

Group type: EXPERIMENTAL
Intervention: Autologous blood injections (ABIs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both ABI and saline groups
Number of subjects: 22
Study: 24322378

Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 323

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Clarification-oriented psychotherapy
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Second-cohort schema therapists
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Interview-based measures
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 323
Study: 22064687

Group type: EXPERIMENTAL
Intervention: On-site monitoring
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Central monitoring techniques
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Participant folder review at site
Number of subjects: 104
Study: 19161758

Group type: EXPERIMENTAL
Intervention: Levosimendan (12 microg/kg bolus, followed by an infusion of 0.2 microg/kg/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17763227

Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin A (BTX‐A; Dysport)
Number of subjects: 31
Study: 14975769

Group type: EXPERIMENTAL
Intervention: Stimulus-irrelevant distracting conversation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stimulus-relevant focused conversation
Number of subjects: 27
Study: 11695208

Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 63

Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 63
Study: 9474184

Group type: EXPERIMENTAL
Intervention: 3-month course of 300 mg neoadjuvant cyproterone acetate daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 213
Study: 7754260

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2371437

Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g twice daily with probenecid
Number of subjects: 6

Group type: COMPARATOR
Intervention: High dose amoxycillin 3 g twice daily
Number of subjects: 6
Study: 782773

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dextroamphetamine sulfate and 50 mug/kg THC from marihuana cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dextroamphetamine sulfate and 25 mug/kg THC from marihuana cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dextroamphetamine and marihuana
Number of subjects: 0
Study: 31315685

Group type: EXPERIMENTAL
Intervention: Text messages with information on job openings plus information on HIV prevention, business educational sessions, a mentored apprenticeship, and a start‐up grant, and business and HIV prevention text messages based on principles from behavioral economics.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Text messages with information on job openings.
Number of subjects: 40
Study: 27254132

Group type: EXPERIMENTAL
Intervention: Assisted Autogenic Drainage (AAD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation (IPV)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bouncing (Control Group)
Number of subjects: 103
Study: 25840525

Group type: EXPERIMENTAL
Intervention: Barbed 3/0 V‐Loc™180 suture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Smooth 3/0 Maxon™ sutures
Number of subjects: 33
Study: 23216615

Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban, twice daily
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: 5 mg apixaban, twice daily
Number of subjects: 2482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study: 21216852

Group type: EXPERIMENTAL
Intervention: Insulin infusion during normoglycemia
Number of subjects: 102
Study: 18359423

Group type: EXPERIMENTAL
Intervention: Clinical characteristics measured at baseline and day 3
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Duration of ventilation before enrollment
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Presence of neurologic disease at admission
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Failure of the Pao2/Fio2 ratio to improve by day 3
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Persistence of fever
Number of subjects: 563
Study: 16919577

Group type: EXPERIMENTAL
Intervention: Community volunteers
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Cardiac patients with LVEF >= 0.50
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Cardiac patients with LVEF < 0.50
Number of subjects: 848
Study: 14514589

Group type: EXPERIMENTAL
Intervention: Inhaled regular insulin (80, 160, or 240 units) via Aerodose insulin inhaler
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subcutaneously injected regular insulin (8, 16, or 24 units)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of total insulin absorption (insulin AUC) versus total metabolic effect (GIR-AUC)
Number of subjects: 24
Study: 10718776

Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg single oral dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Iohexol clearance (predictor of renal function)
Number of subjects: 21
Study: 9388983

Group type: EXPERIMENTAL
Intervention: Heng Nai Jin, a high energy liquid diet
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 1417176

Group type: EXPERIMENTAL
Intervention: Immunochemosurgery (n = 73)
Number of subjects: 6589

Group type: EXPERIMENTAL
Intervention: Immunochemosurgery (n = 159)
Number of subjects: 6589

Group type: COMPARATOR
Intervention: Surgery alone (n = 64)
Number of subjects: 6589

Group type: COMPARATOR
Intervention: Surgery and chemotherapy (n = 77)
Number of subjects: 6589

Group type: COMPARATOR
Intervention: Surgery alone (n = 94)
Number of subjects: 6589
Study: 6496418

Group type: EXPERIMENTAL
Intervention: Experimental group (poison-warning stickers after education)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 20
Study: 31941594

Group type: EXPERIMENTAL
Intervention: Single-docking robotic-assisted nephroureterectomy (RRNU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Laparoscopic radical nephroureterectomy (LRNU)
Number of subjects: 29
Study: 31484331

Group type: EXPERIMENTAL
Intervention: Chilled potatoes (high RS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Boiled potatoes (low RS)
Number of subjects: 30
Study: 26365441

Group type: EXPERIMENTAL
Intervention: SentiMag®
Number of subjects: 193

Group type: COMPARATOR
Intervention: 99m Tc
Number of subjects: 193
Study: 25586295

Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate (75mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel bisulfate (75mg)
Number of subjects: 0
Study: 24676274

Group type: EXPERIMENTAL
Intervention: Spanish animated video about diabetes
Number of subjects: 240

Group type: COMPARATOR
Intervention: Easy to read diabetes information from the National Institute of Diabetes and Digestive and Kidney Diseases (control)
Number of subjects: 240
Study: 22199063

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment, twice daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.05% fluticasone propionate cream, once daily for 6 months
Number of subjects: 60
Study: 21589776

Group type: EXPERIMENTAL
Intervention: Massage therapy (head, neck, face, shoulder, hand, leg, and back massage every night for one month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention except standard treatment)
Number of subjects: 60
Study: 18416219

Group type: EXPERIMENTAL
Intervention: Low molecular starch in combination with Ringer Lactate solution (LMSRL)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Gelatin plasma expanding (GPE)
Number of subjects: 180
Study: 15812403

Group type: EXPERIMENTAL
Intervention: PEG placement with overtube (Group I)
Number of subjects: 73

Group type: COMPARATOR
Intervention: PEG placement without overtube (Group II)
Number of subjects: 73
Study: 12733605

Group type: EXPERIMENTAL
Intervention: Resistance tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (no resistance tests)
Number of subjects: 0
Study: 9477047

Group type: EXPERIMENTAL
Intervention: Monitored group (n = 14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 MAC group (n = 9)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1.3 MAC group (n = 6)
Number of subjects: 44
Study: 7880161

Group type: EXPERIMENTAL
Intervention: Feedback provided to staff concerning the lifestyle of participants
Number of subjects: 33
Study: 2224167

Group type: EXPERIMENTAL
Intervention: First line chemotherapy (monthly FEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loco-regional metastases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant adriamycin containing regimen
Number of subjects: 0
Study: 487347

Group type: EXPERIMENTAL
Intervention: Disulfiram implant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-implant control
Number of subjects: 100
Study: 30157531

Group type: EXPERIMENTAL
Intervention: Oatmeal intervention for 2 days during a 5-day hospital stay
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diabetes adapted diet only (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oatmeal intervention
Number of subjects: 15
Study: 27869305

Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, or 12 mg
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Perampanel (SGS group)
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Placebo (SGS group)
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg (PGTCS group)
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Placebo (PGTCS group)
Number of subjects: 1643
Study: 26536865

Group type: EXPERIMENTAL
Intervention: Home-based self-sampling for HPV testing
Number of subjects: 1521

Group type: EXPERIMENTAL
Intervention: Self-sampling participation
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Non-participation in self-sampling
Number of subjects: 1521
Study: 23664436

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1435
Study: 21059666

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (3 times a week for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program
Number of subjects: 24
Study: 19526809

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (anesthetized with sevoflurane and intermittent i.v. sulfenany and vecurnium bromide)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of TAES and Control
Number of subjects: 50
Study: 17945070

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae vaccination as an adjunct to anti-tuberculosis treatment
Number of subjects: 751

Group type: COMPARATOR
Intervention: Control group (anti-tuberculosis treatment without Mycobacterium vaccae vaccination)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Comparison of mortality between sites
Number of subjects: 751
Study: 16297299

Group type: COMPARATOR
Intervention: Normal saline (group NS), 15 infants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polyelectrolyte solution (group PS), 21 infants
Number of subjects: 36
Study: 11916817

Group type: EXPERIMENTAL
Intervention: Size 3 ILM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Size 4 ILM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Size 5 ILM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All ILM sizes
Number of subjects: 100
Study: 9895265

Group type: EXPERIMENTAL
Intervention: Urolase fiber
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ultraline fiber
Number of subjects: 93
Study: 7608359

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 1044

Group type: COMPARATOR
Intervention: No gum use
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Self-help materials
Number of subjects: 1044

Group type: COMPARATOR
Intervention: No use of materials
Number of subjects: 1044
Study: 2375819

Group type: EXPERIMENTAL
Intervention: Empathy skills training course
Number of subjects: 0
Study: 709021

Group type: EXPERIMENTAL
Intervention: Hypaque 85
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urografin 76
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 40
Study: 30617130

Group type: EXPERIMENTAL
Intervention: A+AVD (doxorubicin, vinblastine, dacarbazine plus brentuximab vedotin)
Number of subjects: 497

Group type: COMPARATOR
Intervention: ABVD (doxorubicin, vinblastine, dacarbazine, and bleomycin)
Number of subjects: 497
Study: 28782136

Group type: EXPERIMENTAL
Intervention: 4 month multi-faceted intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-adjacent county sports clubs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 26814307

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1,200 mg
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 2,400 mg
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 3,600 mg
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 24665887

Group type: EXPERIMENTAL
Intervention: Forsus device (FRD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated Class II malocclusion)
Number of subjects: 36
Study: 22993294

Group type: EXPERIMENTAL
Intervention: STX209 (arbaclofen)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 20201934

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 245
Study: 17698196

Group type: COMPARATOR
Intervention: Focal photocoagulation at baseline (n = 19)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks (n = 22)
Number of subjects: 121
Study: 16417695

Group type: EXPERIMENTAL
Intervention: Telephone call from a nurse
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Letter from a well-known celebrity (Claire Rayner)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Letter from the local NHS Cervical Screening Commissioner
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Control group (no action)
Number of subjects: 1140
Study: 12421428

Group type: EXPERIMENTAL
Intervention: 50% insulin lispro and 50% neutral protamine lispro (Mix50)
Number of subjects: 109
Study: 10523401

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 1 (on awakening)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 2 (8 hours after awakening)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d, starting at 12 to 16 weeks of gestation, administered at time 3 (before bedtime)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Aspirin (any time) for women with a positive tolerance-hyperbaric test
Number of subjects: 240

Group type: COMPARATOR
Intervention: Aspirin or placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Aspirin (any time)
Number of subjects: 240
Study: 7573253

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure (maternal prenatal exposure)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Unexposed to diethylstilbestrol (control group)
Number of subjects: 542
Study: 2147831

Group type: EXPERIMENTAL
Intervention: Enoximone 50 micrograms/kg/min for 30 minutes then 10 micrograms/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine 10 micrograms/kg/min
Number of subjects: 20
Study: 388762

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) - 14 daily doses in addition to standard immunosuppressive therapy (azathioprine and prednisone)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group - no ATG
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) - 14 daily doses
Number of subjects: 358
Study: 31172407

Group type: EXPERIMENTAL
Intervention: GC+w‐iniparib (iniparib 11.2 mg/kg on days 1 and 8 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: GC+tw‐iniparib (iniparib 5.6 mg/kg on days 1, 4, 8, and 11 with gemcitabine 1000 mg/m2 and carboplatin AUC 2 every 3 weeks)
Number of subjects: 163
Study: 29190741

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS)
Number of subjects: 40
Study: 26835867

Group type: EXPERIMENTAL
Intervention: Intervention program on recommended sleeping position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 20
Study: 23938061

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25 to 4 mg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 21761740

Group type: EXPERIMENTAL
Intervention: Maixuekang capsule
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low molecular heparin calcium (Subilin)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Maixuekang capsule and low molecular heparin calcium (Subilin)
Number of subjects: 214
Study: 19969158

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 3 times a week for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Home exercise (relaxation/stretching) program
Number of subjects: 50
Study: 16413249

Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 9
Study: 15288906

Group type: EXPERIMENTAL
Intervention: Moving school
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional school
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 11740289

Group type: EXPERIMENTAL
Intervention: Multi-station proprioceptive exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 9415513

Group type: EXPERIMENTAL
Intervention: Monozygotic twins (MZ)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Dizygotic twins (DZ)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Adjustment for confounding variables
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Reliability of dolorimeter measurements
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Heritability of PPT
Number of subjects: 609
Study: 8237624

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 80